Friday, March 17, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

SIGA Gets Greenlight on Smallpox Drug Phase 3 Trial

by Global Biodefense Staff
February 24, 2016
Smallpox

Smallpox Variola VaccineSIGA Technologies, Inc. today announced the receipt of FDA concurrence on a dose for continuing the pivotal clinical human safety study for tecovirimat, an antiviral pharmaceutical to treat orthopoxvirus-related diseases, including smallpox.

Smallpox has been determined to be a material threat to US security and is classified by CDC as a Class A priority pathogen.

The concurrence on dosage for tecovirimat, also known as TPOXX and ST-246, provides SIGA with the guidance it needs to complete its Phase 3 expanded safety trial in human subjects for the oral formulation of tecovirimat.

“We are pleased to receive FDA concurrence on dosage for our clinical safety studies and look forward to the future development and distribution of this critical antiviral,” said Dr. Eric Rose, SIGA’s Chief Executive Officer.

FDA has designated tecovirimat for “fast-track” status, creating a path for expedited FDA review and eventual regulatory approval. Tecovirimat is a novel, patented drug that is easy to store, transport and administer.

In May 2011, SIGA signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) pursuant to which SIGA agreed to deliver two million courses of tecovirimat to the U.S. Strategic National Stockpile. The BARDA contract is worth approximately $463 million, including $409.8 million for the manufacture and delivery of 1.7 million courses of tecovirimat and $54 million of potential reimbursements related to development and supportive activities under a base contract. The contract also contains various options that are exercisable at BARDA’s discretion.

The BARDA contract expires in September 2020.

See also:

  • Development of the small-molecule antiviral ST-246 as a smallpox therapeutic (NCBI)
  • Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (NCBI)
Tags: AntiviralsASPRBARDAHHSNIHPoxvirusesSmallpox

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC